Review

Total pancreatectomy and islet cell autotransplantation: Definitive treatment for chronic pancreatitis

Karla M. Arce, MD, Yu Kuei Lin, MD, Tyler Stevens, MD, R. Matthew Walsh, MD and Betul A. Hatipoglu, MD
Cleveland Clinic Journal of Medicine June 2016, 83 (6) 435-442; DOI: https://doi.org/10.3949/ccjm.83a.15056

This article has a correction. Please see:

ABSTRACT

In appropriately selected patients, total pancreatectomy and islet cell autotransplant controls pain and improves quality of life while often minimizing the development of overt diabetes. Multidisciplinary management and lifelong follow-up help to maximize the benefit of this procedure. This review highlights its history, indications, metabolic outcomes, and future directions.

Footnotes

  • Dr. Stevens has disclosed teaching and speaking for Abbvie Pharmaceuticals and Boston Scientific, and consulting and other activities for Boston Scientific.

View Full Text
  1. Karla M. Arce, MD
  1. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  1. Yu Kuei Lin, MD
  1. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  1. Tyler Stevens, MD
  1. Department of Gastroenterology and Hepatology, Cleveland Clinic
  2. Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. R. Matthew Walsh, MD
  1. Department of General Surgery, Cleveland Clinic
  2. Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Betul A. Hatipoglu, MD⇑
  1. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  2. Clinical Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. ADDRESS:
    Betul A. Hatipoglu, MD, Department of Endocrinology, Diabetes, and Metabolism, F20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hatipoglub{at}ccf.org

ABSTRACT

In appropriately selected patients, total pancreatectomy and islet cell autotransplant controls pain and improves quality of life while often minimizing the development of overt diabetes. Multidisciplinary management and lifelong follow-up help to maximize the benefit of this procedure. This review highlights its history, indications, metabolic outcomes, and future directions.

Footnotes

  • Dr. Stevens has disclosed teaching and speaking for Abbvie Pharmaceuticals and Boston Scientific, and consulting and other activities for Boston Scientific.

View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects